Finanzen von MIRA Pharmaceuticals Inc (MIRA)MIRAMIRA Pharmaceuticals Inc

Evaluating the bottom line, MIRA Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -710.85%, provide a clear picture of how effectively MIRA converts its operational activities into shareholder value.

In the context of the broader market, MIRA competes directly with industry leaders such as SCLX and NAII. With a market capitalization of $32.79M, it holds a significant position in the sector. When comparing efficiency, MIRA's gross margin of N/A stands against SCLX's 24.51% and NAII's 1.08%. Such benchmarking helps identify whether MIRA Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

The company has consistently reported negative net income, with the latest quarterly net income at -1,208,534 USD. The current ratio is 0.00 for Q2 2026, indicating potential liquidity issues. The price-to-book ratio is 3.96, suggesting the stock is trading at a premium compared to its book value.